Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Castrate Resistant Prostate Cancer × Clear all

Phase

Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 90 Neoplasms 88 Carcinoma, Non-Small-Cell Lung 67 Prostatic Neoplasms 61 Colorectal Neoplasms 59 Carcinoma, Hepatocellular 56 Leukemia, Myeloid, Acute 50 Neoplasm Metastasis 45 Stomach Neoplasms 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Lung Neoplasms 38 Pancreatic Neoplasms 32 Recurrence 30 Multiple Myeloma 27 Rectal Neoplasms 25 Colonic Neoplasms 24 Leukemia 23 Head and Neck Neoplasms 23 Ovarian Neoplasms 21 Lymphoma 21 Squamous Cell Carcinoma of Head and Neck 20 Hematologic Neoplasms 19 Esophageal Neoplasms 18 Polycystic Ovary Syndrome 17 Myelodysplastic Syndromes 17 Urinary Bladder Neoplasms 16 Melanoma 15 Lymphoma, Large B-Cell, Diffuse 15 Liver Neoplasms 15 Glioblastoma 15

Interventions

Melphalan 1 Lenograstim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01907009 2023-04-19

MEL-CAP

Barts & The London NHS Trust

Phase 2/3 Terminated

Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡